Assembly Biosciences, Inc. (ASMB)
| Market Cap | 513.62M +256.7% |
| Revenue (ttm) | 71.10M +121.1% |
| Net Income | -6.38M |
| EPS | -0.47 |
| Shares Out | 19.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 119,771 |
| Open | 27.07 |
| Previous Close | 26.45 |
| Day's Range | 26.36 - 27.12 |
| 52-Week Range | 19.13 - 39.71 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 50.00 (+87.41%) |
| Earnings Date | Aug 14, 2026 |
About ASMB
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next g... [Read more]
Financial Performance
In 2025, Assembly Biosciences's revenue was $72.30 million, an increase of 153.52% compared to the previous year's $28.52 million. Losses were -$6.12 million, -84.76% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ASMB stock is "Strong Buy." The 12-month stock price target is $50.0, which is an increase of 87.41% from the latest price.
News
Assembly Biosciences price target raised to $45 from $40 at Mizuho
Mizuho raised the firm’s price target on Assembly Biosciences (ASMB) to $45 from $40 and keeps an Outperform rating on the shares. The firm updated the company’s model post the…
Assembly Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing HSV-2 and liver disease programs, with strong phase I data and a key partnership accelerating HSV-2 development. Upcoming milestones include a profit-share decision, phase II data for HSV-2 and hep delta, and expansion into cholestatic liver diseases.
Assembly Biosciences Transcript: AGM 2026
The meeting covered board elections, executive compensation, auditor ratification, and amendments to incentive and stock purchase plans. All proposals passed with a quorum present, and no questions were raised by shareholders.
Assembly Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Multiple clinical programs are advancing, with key catalysts expected for HSV and hepatitis delta. ABI-6250 is expanding into PBC and PSC, with Phase II trials and data on the horizon. Financial runway extends into 2028, and partnering discussions for hepatitis B assets are ongoing.
Assembly Biosciences Announces Upcoming Investor Conference Presentations
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di...
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di...
Assembly Biosciences announces expansion of ABI-6250 clinical development
Assembly Biosciences (ASMB) announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus infection, into primary biliary cholang...
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di...
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV –
Assembly Biosciences Transcript: Bank of America Global Healthcare Conference 2026
The discussion highlighted progress in advancing antiviral candidates for HSV and hepatitis D, with strong early clinical data and strategic partnerships driving pipeline momentum. Oral therapies aim to address unmet needs in efficacy, convenience, and transmission, with key data readouts expected by 2027.
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to...
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to...
Assembly Biosciences reports Q1 EPS (54c), consensus (64c)
Reports Q1 revenue $8.21M, consensus $6.95M. “The first quarter reflected steady progress across our portfolio as we continue advancing our discovery and development programs,” said Jason Okazaki, chi...
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inh...
Assembly Biosciences Quarterly report: Q1 2026
Assembly Biosciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Assembly Biosciences Earnings release: Q1 2026
Assembly Biosciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Assembly Biosciences Slides: Corporate presentation
Assembly Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Assembly Biosciences Proxy statement: Proxy filing
Assembly Biosciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Assembly Biosciences Proxy statement: Proxy filing
Assembly Biosciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – SO...
Assembly Biosciences price target raised to $43 from $39 at Guggenheim
Guggenheim raised the firm’s price target on Assembly Biosciences (ASMB) to $43 from $39 and keeps a Buy rating on the shares. The firm is updating its Assembly model to…
Assembly Biosciences files $400M mixed securities shelf
17:05 EDT Assembly Biosciences (ASMB) files $400M mixed securities shelf
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development pla...
Assembly Biosciences Annual report: Q4 2025
Assembly Biosciences has published its Q4 2025 annual report on March 19, 2026.
Assembly Biosciences Earnings release: Q4 2025
Assembly Biosciences released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.